Real-world Experience of Catheter Ablation for the Treatment of Arrhythmias

Prior treatment

• Enrolled in an investigational drug or device clinical trial, or any trial that dictates the treatment plan
• Enrolled in an investigational drug or device clinical trial, or any trial that dictates the treatment plan.

Other

• Long-standing persistent AF (AF greater than one year)
• In the opinion of the investigator, any known contraindication to an ablation procedure
  • CORE VA Cohort
• In the opinion of the investigator, any known contraindication to an ablation procedure.

• Symptomatic PAF (AF episode terminate spontaneously within 7 days) or PsAF (AF sustained beyond 7 days, but less than 365 days) subjects who, in the opinion of the investigator, are candidates for catheter ablation.
• \>18 years of age.
• Will be treated with Biosense Webster Inc. ablation technologies
• All AF ablations performed with BWI catheters are included. This includes repeat ablations where the index procedure was performed with a non-BWI catheter.
• Able and willing to participate in baseline and follow up evaluations
• Willing and able to provide informed consent, if applicable.
• Documented ventricular arrhythmia appropriate for catheter ablation.
• \>18 years of age.
• Will be treated with Biosense Webster Inc. ablation technologies
• Able and willing to participate in baseline and follow up evaluations
• Willing and able to provide informed consent, if applicable.

Criteria the registry did not label

• REAL AF Cohort